Open access · CC-BY
via OpenAlex
Clinical evidence for the use of NAD+ precursors to slow aging
Subhash Khatri, Mahmoud Abdellatif, Simon Sedej
Geromedicine · 2025 · ▲ 2 citations
Genomic instability
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Human
Preclinical / animal
Review
Abstract
Significant progress in clinical care has extended human life expectancy to unprecedented levels. However, this trend has been parallelled by a rise in years lived with poor health, posing profound challenges not only to individual quality of life, but also to substantial medical and socioeconomic burdens at the population level. This underscores the urgent need for strategies that extend healthspan(definition) alongside lifespan. In this regard, nicotinamide adenine dinucleotide (NAD+) has emerged as a central metabolic cofactor and signaling molecule that regulates processes fundamental to health and longevity, including energy metabolism, mitochondrial function, inflammation, and DNA repair. Importantly, intracellular NAD+ levels decline with age across multiple tissues and organ systems, and restoring NAD+ content has been shown to reinstate cellular and physiological function in various model systems. Among the strategies to augment NAD+, supplementation with its precursors, namely nicotinic acid/niacin, nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide, represents the most practical and extensively studied approach. Over the past two decades, preclinical research and an increasing number of clinical trials have investigated the therapeutic potential of these precursors in preventing or reversing age-associated decline and pathologies. In this review, we synthesize recent clinical advances, critically evaluate the promise and limitations of NAD+ precursor supplementation, and discuss future directions for leveraging NAD+ metabolism to improve healthspan in a rapidly aging global population.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.70401/geromedicine.2025.0008
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Khatri, S., Abdellatif, M., & Sedej, S. (2025). Clinical evidence for the use of NAD+ precursors to slow aging. <em>Geromedicine</em>. https://doi.org/10.70401/geromedicine.2025.0008
Vancouver
Khatri S, Abdellatif M, Sedej S. Clinical evidence for the use of NAD+ precursors to slow aging. Geromedicine. 2025. doi:10.70401/geromedicine.2025.0008.
BibTeX
@article{subhash2025Clinic,
title = {Clinical evidence for the use of NAD+ precursors to slow aging},
author = {Subhash Khatri and Mahmoud Abdellatif and Simon Sedej},
journal = {Geromedicine},
year = {2025},
doi = {10.70401/geromedicine.2025.0008},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Open Science Framework 2025
Preprint · CC-BY
Effects of NAD⁺-Boosting Interventions on Human Aging: A Systematic Review and Meta-analysis Protocol
Aging and Disease 2023
Open access · CC-BY
Role and Potential Mechanisms of Nicotinamide Mononucleotide in Aging
Journal of bioenergetics and biomembranes 2026
Citation only
Revitalizing aging muscles: harnessing NAD⁺, sirtuins, and exercise to combat sarcopenia.
International Journal of Molecular Sciences 2021
Open access · CC-BY
Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process
Novel Techniques in Nutrition & Food Science 2025
Open access · CC-BY
Nicotinamide Riboside and NAD+ Decline: Hype vs. Evidence
Cosmoderma 2026
Open access · CC-BY